Dexmedetomidine prevent postoperative nausea and vomiting on patients during general anesthesia

Jin, Shenhui; Liang, Dong; Chen, Chengyu; Zhang, Minyuan; Wang, Junlu

doi:10.1097/md.0000000000005770

Cited by 80 publications

(84 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As an α2 adrenergic receptor agonist, it decreases sympathetic activity by reducing level of catecholamine and/or its opioid-sparing effect (18). Two meta-analysis suggested that administration of dexmedetomidine decrease the incidence of PONV (15,19). This finding was consistent with our study as both MC and FC group has had the higher number of PONV patients, and the number of patients decreased as the dosage of dexmedetomidine increased.…”

Section: Discussionsupporting

confidence: 82%

The influence of dexmedetomidine on remifentanil‑induced hyperalgesia and the sex differences

et al. 2018

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

The influence of dexmedetomidine on remifentanil‑induced hyperalgesia and the sex differences

et al. 2018

View full text Add to dashboard Cite

“…Dexmedetomidine is strong, and a highly selective α - 2 agonist that attaches to a transmembrane G - protein coupled receptor in the brain and spinal cord, and affects the function of the central nervous system and the central circulatory system to produce its analgesic and sympathetic effects [ 7 ]. Dexmedetomidine is potentially used in anaesthesia and intensive care units due to its anxiolytic, analgesic, and sympathetic effects as well as its hemodynamic constants [ 7 ] [ 8 ]. Regarding available evidence, PONV is one of the main complaints of surgery and anaesthesia and is one of the risk factors for vomiting after abdominal surgery, such as abdominal hysterectomy.…”

Section: Introductionmentioning

confidence: 99%

Investigation of Ondansetron, Haloperidol, and Dexmedetomidine Efficacy for Prevention of Postoperative Nausea and Vomiting In Patients with Abdominal Hysterectomy

Kamali¹,

Ahmadi²,

Shokrpour³

et al. 2018

Open Access Maced J Med Sci

View full text Add to dashboard Cite

AIM:This study was aimed to compare the effects of ondansetron, haloperidol, and dexmedetomidine for reducing postoperative nausea and vomiting (PONV) after laparoscopic cholecystectomy.METHODS:This randomised clinical trial study was performed on p.patients who were candidates for abdominal hysterectomy referring to Taleghani hospital in Arak. In this study, 114 patients with abdominal hysterectomy were randomly assigned to three groups (ondansetron, haloperidol, and dexmedetomidine) using the cubull randomisation method.RESULTS:The results revealed a significant difference between the three groups of ondansetron, haloperidol and dexmedetomidine in terms of scorpion vomiting in recovery, 2 and 4 hours after surgery, and vomiting score was significantly lower in the ondansetron group compared with the other two groups (P = 0.04; P = 0.02; P = 0.001). There was a significant difference between the three groups of e ondansetron, haloperidol and dexmedetomidine regarding the mean dose of metoclopramide in mg for 24 hours after surgery. Therefore, the dosage of dexmedetomidine in the ondansetron group was less than the other two groups (P = 0.001).CONCLUSION:these three drugs are effective in reducing PONV in patients undergoing a hysterectomy. However, the effect of ondansetron was found to be more than the other two drugs in reducing PONV.

show abstract

“…Additionally, Bielka K et al found that dexmedetomidine infusion at rate of 0.5 μg/kg/h from induction of anaesthesia to extubation was reduced the incidence of PONV in patients after laparoscopic cholecystectomy (OR 5, 95% CI 1.1-26, p=0.005) [23]. Meta-analyses of clinical trials had similar results, that is, dexmedetomidine infusion during the anesthesia period decreased the incidence of PONV [24]. Suzuki T et al have revealed that patients who were received dexmedetomidine administration had much lower incidence of PONV than those who were received NLA [25].…”

Section: Discussionmentioning

confidence: 91%

Effect of intravenous lidocaine combined with dexmedetomidine on postoperative nausea and vomiting after laparoscopic total hysterectomy

Xu¹,

Ju²,

Wang³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background A few studies have manifested that intravenous (IV) lidocaine or dexmedetomidine decreased the incidence of postoperative nausea and vomiting (PONV). We investigated whether lidocaine plus dexmedetomidine infusion could better reduce the incidence of PONV than placebo after laparoscopic total hysterectomy. Methods This prospective, randomized controlled study enrolled 126 women undergoing elective laparoscopic total hysterectomy with general anesthesia. They divided into the following two groups: patients in the lidocaine combined with dexmedetomidine group (group LD) received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine (0.5 μg/kg loading, 0.4 μg/kg/h infusion), respectively. Patients in the control group (group CON) received the equal volume of saline. The primary outcome was the incidence of nausea, vomiting and PONV for the first 48 hours after surgery. The secondary outcomes included intraoperative propofol and remifentanil consumption, postoperative fentanyl requirement, Ramsay sedation score, and the incidence of bradycardia during post-anesthesia care unit (PACU) stay period. Results Data of 59 in CON and 60 in LD groups were analyzed. The incidence of nausea, vomiting, and PONV in group LD during the 0 to 2 hours and 24 to 48 hours after the operation was slightly lower than group CON, but the difference was not statistically significant between the two groups. The incidence of nausea, vomiting, and PONV was much lower in group LD than group CON at 2 to 24 hours after surgery (P<0.05, P<0.01, P<0.01, respectively). The cumulative requirement of fentanyl during the first 48 hours after surgery was significantly reduced in group LD compared to group CON (P<0.01, P<0.01, P<0.05, respectively). Propofol and remifentanil total dose in the intraoperative period was significantly lower in group LD compared with group CON (P<0.01 and P<0.01). However, the level of sedation and incidence of bradycardia during the PACU stay period were markedly increased in group LD compared with group CON (P<0.01 and P<0.01). Conclusion Lidocaine plus dexmedetomidine infusion markedly decreased the occurrence of nausea, vomiting and PONV within the 2 to 24 hours after laparoscopic total hysterectomy with general anesthesia. However, it increased the incidence of bradycardia and the level of sedation during the PACU stay period.

show abstract

Dexmedetomidine prevent postoperative nausea and vomiting on patients during general anesthesia

Abstract: Supplemental Digital Content is available in the text

Cited by 80 publications

References 41 publications

The influence of dexmedetomidine on remifentanil‑induced hyperalgesia and the sex differences

The influence of dexmedetomidine on remifentanil‑induced hyperalgesia and the sex differences

Investigation of Ondansetron, Haloperidol, and Dexmedetomidine Efficacy for Prevention of Postoperative Nausea and Vomiting In Patients with Abdominal Hysterectomy

Effect of intravenous lidocaine combined with dexmedetomidine on postoperative nausea and vomiting after laparoscopic total hysterectomy

Contact Info

Product

Resources

About